Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of sorafenib in patients
with PAH already on existing therapy with a prostacyclin [epoprostenol (Flolan)],
treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).